Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Receives $4.79 Consensus Target Price from Brokerages

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) has received a consensus rating of “Hold” from the eleven ratings firms that are presently covering the firm, MarketBeat.com reports. Eight research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $4.79.

Several equities research analysts have weighed in on the stock. EF Hutton Acquisition Co. I raised shares of Marinus Pharmaceuticals to a “strong-buy” rating in a report on Monday, September 30th. JMP Securities reiterated a “market perform” rating on shares of Marinus Pharmaceuticals in a report on Thursday, October 24th. Truist Financial downgraded Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 24th. HC Wainwright reiterated a “neutral” rating and issued a $2.00 price objective on shares of Marinus Pharmaceuticals in a report on Thursday, November 14th. Finally, Royal Bank of Canada reduced their target price on Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating on the stock in a research note on Friday, October 25th.

Institutional Trading of Marinus Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Hussman Strategic Advisors Inc. grew its holdings in Marinus Pharmaceuticals by 14.3% in the second quarter. Hussman Strategic Advisors Inc. now owns 84,000 shares of the biopharmaceutical company’s stock worth $98,000 after purchasing an additional 10,500 shares during the period. AQR Capital Management LLC boosted its position in shares of Marinus Pharmaceuticals by 70.3% in the 2nd quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 12,934 shares in the last quarter. Point72 DIFC Ltd purchased a new stake in shares of Marinus Pharmaceuticals in the 2nd quarter worth approximately $28,000. SG Americas Securities LLC bought a new position in Marinus Pharmaceuticals during the 2nd quarter valued at approximately $34,000. Finally, Values First Advisors Inc. raised its stake in Marinus Pharmaceuticals by 501.8% during the second quarter. Values First Advisors Inc. now owns 62,671 shares of the biopharmaceutical company’s stock valued at $73,000 after buying an additional 52,257 shares during the last quarter. 98.80% of the stock is owned by hedge funds and other institutional investors.

Marinus Pharmaceuticals Stock Performance

NASDAQ:MRNS opened at $0.24 on Friday. Marinus Pharmaceuticals has a fifty-two week low of $0.23 and a fifty-two week high of $11.26. The firm has a market cap of $13.44 million, a PE ratio of -0.10 and a beta of 1.25. The business has a 50 day moving average price of $0.60 and a 200-day moving average price of $1.14.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.